scholarly journals Salicylate administration suppresses the inflammatory response to nutrients and improves ovarian function in polycystic ovary syndrome

2020 ◽  
Vol 319 (4) ◽  
pp. E744-E752
Author(s):  
Frank González ◽  
Kieren J. Mather ◽  
Robert V. Considine ◽  
Ola A. Abdelhadi ◽  
Anthony J. Acton
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Mononuclear Cells ◽  
Ovarian Function ◽  
Polycystic Ovary ◽  
Reactive Oxygen Species Generation ◽  
Endogenous Glucose Production ◽  
Glucose Disposal ◽  
Ovary Syndrome ◽  
Before And After ◽  
Androgen Secretion

Oxidative stress (OS) and inflammation are often present in polycystic ovary syndrome (PCOS). We examined the effects of salsalate treatment on nutrient-induced OS and inflammation, ovarian androgen secretion, ovulation, and insulin sensitivity in PCOS. Eight lean insulin-sensitive women with PCOS and eight age- and body composition-matched ovulatory controls for baseline comparison participated in the study. The women with PCOS underwent a 12-wk treatment of salsalate, a nonsteroidal anti-inflammatory drug, at a dose of 3 g daily. Markers of OS and inflammation were quantified in mononuclear cells (MNC) and plasma from blood drawn fasting and 2 h after saturated fat ingestion before and after treatment. Ovarian androgen secretion was assessed from blood drawn fasting and 24, 48, and 72 h after human chorionic gonadotropin (HCG) administration before and after treatment. Ovulation was documented based on biphasic basal body temperatures and luteal range progesterone elevations. A two-step pancreatic clamp was performed pre- and posttreatment to measure basal endogenous glucose production (EGP) and the steady-state glucose disposal rate (GDR) during the euglycemic phase and markers of OS and inflammation in MNC and plasma during the hyperglycemic phase. Salsalate administration suppressed lipid- and glucose-stimulated reactive oxygen species generation, activated nuclear factor-κB and circulating tumor necrosis factor-α, normalized basal androgen levels, and lowered HCG-stimulated androgen secretion without altering EGP or GDR. Four salsalate-treated subjects responded with two consecutive ovulations. We conclude that in PCOS, salsalate-induced suppression of OS and inflammation ameliorates ovarian androgen hypersecretion and may induce ovulation while maintaining insulin action.

scholarly journals Use of Inositols in Polycystic Ovary Syndrome

2020 ◽  
Vol 16 (28) ◽  
pp. 24-34
Author(s):  
O.A. Pustotina ◽  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Ovarian Function ◽  
Polycystic Ovary ◽  
The Body ◽  
Metabolic Parameters ◽  
Ovary Syndrome ◽  
Pathogenetic Role

The article presents key data on the physiology of inositols in the body, their pathogenetic role in the development of polycystic ovary syndrome, and the possibilities of myo-inositol and D-chiro-inositol in the restoration of ovarian function, metabolic parameters, and overcoming of infertility.

Rosiglitazone in insulin-resistant women with polycystic ovary syndrome (PCOS): effects on ovarian function and metabolism

2002 ◽  
Vol 78 ◽  
pp. S36 ◽  
Author(s):  
Nicholas A Cataldo ◽  
Fahim Abbasi ◽  
Tracey L McLaughlin ◽  
Patricia Y Fechner ◽  
Gerald M Reaven ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Ovarian Function ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Insulin Resistant

scholarly journals Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome

2012 ◽  
Vol 166 (4) ◽  
pp. 703-710 ◽  
Author(s):  
Gabriella Donà ◽  
Chiara Sabbadin ◽  
Cristina Fiore ◽  
Marcantonio Bragadin ◽  
Francesco L Giorgino ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Serum Insulin ◽  
Band 3 ◽  
Oral Glucose ◽  
Fasting Serum ◽  
Ovary Syndrome ◽  
Inflammatory Status ◽  
Before And After

ObjectivePossibly due to a deficiency of insulin mediators, polycystic ovary syndrome (PCOS) is often associated with insulin resistance (IR) and hyperinsulinemia, likely responsible for an elevated production of reactive oxygen species. We investigated oxidative-related alterations in erythrocytes and anti-inflammatory effects of inositol in women with PCOS before and after treatment with myo-inositol (MYO).MethodsTwenty-six normal-weight PCOS patients were investigated before and after MYO administration (1200 mg/day for 12 weeks;n=18) or placebo (n=8) by evaluating serum testosterone, serum androstenedione, fasting serum insulin, fasting serum glucose, insulin area under the curve (AUC), and glucose AUC after oral glucose tolerance test and homeostasis model of assessment–IR. In erythrocytes, band 3 tyrosine phosphorylation (Tyr-P) level, glutathione (GSH) content, and glutathionylated proteins (GSSP) were also assessed.ResultsData show that PCOS patients' erythrocytes underwent oxidative stress as indicated by band 3 Tyr-P values, reduced cytosolic GSH content, and increased membrane protein glutathionylation. MYO treatment significantly improved metabolic and biochemical parameters. Significant reductions were found in IR and serum values of androstenedione and testosterone. A significant association between band 3 Tyr-P levels and insulin AUC was found at baseline but disappeared after MYO treatment, while a correlation between band 3 Tyr-P and testosterone levels was detected both before and after MYO treatment.ConclusionsPCOS patients suffer from a systemic inflammatory status that induces erythrocyte membrane alterations. Treatment with MYO is effective in reducing hormonal, metabolic, and oxidative abnormalities in PCOS patients by improving IR.

scholarly journals Clinical and Metabolic Effects of Alpha-Lipoic Acid Associated with Two Different Doses of Myo-Inositol in Women with Polycystic Ovary Syndrome

2020 ◽  
Vol 2020 ◽  
pp. 1-8 ◽  
Author(s):  
Franca Fruzzetti ◽  
Elena Benelli ◽  
Tiziana Fidecicchi ◽  
Massimo Tonacchera
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Lipoic Acid ◽  
Polycystic Ovary ◽  
Insulin Response ◽  
Reproductive Hormones ◽  
Metabolic Effects ◽  
Metabolic Phenotype ◽  
Ovary Syndrome ◽  
Before And After ◽  
Different Doses

The aim of this retrospective study was to evaluate the effects of a treatment with α-lipoic acid (ALA) associated with two different doses of myo-inositol (MI) on clinical and metabolic features of women with polycystic ovary syndrome (PCOS). Eighty-eight women received the treatment, and 71 among them had complete clinical charts and were considered eligible for this study. All women were treated with 800 mg of ALA per day: 43 patients received 2000 mg of MI and 28 received 1000 mg of MI per day. Menstrual cyclicity, BMI, FSH, LH, estradiol, testosterone, androstenedione, fasting insulin, HOMA-IR, and insulin response to a 2 h OGTT were evaluated before and after 6 months of treatment. The presence of diabetic relatives (DRs) was investigated. Cycle regularity was improved in 71.2% of women. The improvement of menstrual cyclicity occurred regardless of the state of IR and the presence of DRs of the patients. Women with IR mainly showed a significant improvement of metabolic parameters, while those without IR had significant changes of reproductive hormones. Patients with DRs did not show significant changes after the treatment. 85.7% of women taking 2000 mg of MI reported a higher improvement of menstrual regularity than those taking 1000 mg of MI (50%; p<0.01). In conclusion, ALA + MI positively affects the menstrual regularity of women with PCOS, regardless of their metabolic phenotype, with a more evident effect with a higher dose of MI. This effect seems to be insulin independent. The presence of IR seems to be a predictor of responsivity to the treatment in terms of an improvement of the metabolic profile.

Sign in / Sign up

Export Citation Format

Share Document